Your browser doesn't support javascript.
loading
GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review.
Syrjänen, Kari; Eskelinen, Matti; Peetsalu, Ants; Sillakivi, Toomas; Sipponen, Pentti; Härkönen, Matti; Paloheimo, Lea; Mäki, Minna; Tiusanen, Tapani; Suovaniemi, Osmo; DiMARIO, Francesco; Fan, Zhu Ping.
Afiliación
  • Syrjänen K; Department of Clinical Research, Biohit Oyj, Helsinki, Finland kasyrja@netti.fi.
  • Eskelinen M; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • Peetsalu A; Department of Surgery, Kuopio University Hospital, Kuopio, Finland.
  • Sillakivi T; Department of Surgery, University of Tartu, Tartu, Estonia.
  • Sipponen P; Department of Surgery, University of Tartu, Tartu, Estonia.
  • Härkönen M; Patolab Oy, Espoo, Finland.
  • Paloheimo L; Department of Clinical Research, Biohit Oyj, Helsinki, Finland.
  • Mäki M; Department of Research and Development, Biohit Oyj, Helsinki, Finland.
  • Tiusanen T; Department of Research and Development, Biohit Oyj, Helsinki, Finland.
  • Suovaniemi O; Department of Research and Development, Biohit Oyj, Helsinki, Finland.
  • DiMARIO F; Department of Clinical Research, Biohit Oyj, Helsinki, Finland.
  • Fan ZP; Department of Research and Development, Biohit Oyj, Helsinki, Finland.
Anticancer Res ; 39(3): 1091-1104, 2019 Mar.
Article en En | MEDLINE | ID: mdl-30842138
BACKGROUND/AIM: Several clinical conditions seriously hamper the diagnostic accuracy of the commonly used tests for Helicobacter pylori (Hp), 13C-urea breath test (UBT) and stool antigen test (SAT). The present communication is a critical review of the potential limitations of UBT and SAT, and describes the approach on how these can be avoided. Drawbacks of the Hp tests: False-negative results are most often due to low bacterial load in the stomach due to: i) use of proton pump inhibitor medication; ii) use of antibiotics; iii) presence of atrophic gastritis and hypoacid stomach; iv); bleeding peptic ulcer; v) gastric cancer (GC) and vi) mucosal-associated lymphatic tissue lymphoma. The UBT also gives false-positive results when urease-producing bacterial species, other than Hp colonize an acid-free stomach. Importantly, neither UBT nor SAT are capable of diagnosing atrophic gastritis, thus missing the patients at highest risk for GC. GastroPanel® (Biohit Oyj, Finland) circumvents these shortcomings with a serological test consisting of a panel of stomach-specific biomarkers: pepsinogen I, pepsinogen II, gastrin-17 and Hp antibodies. GastroPanel® is a tool for non-invasive examination of i) dyspeptic patients for exclusion or diagnosis of Hp or atrophic gastritis, also disclosing the status of gastric acid output; ii) for screening of asymptomatic individuals at risk of GC; and iii) for comprehensive diagnosis of Hp infection. GastroSoft® application integrates the biomarker profile with the patient's medical information, accurately classifying the biomarker profiles into eight diagnostic categories. CONCLUSION: Given that Hp is the single most important risk factor of GC, the non-invasive diagnosis and screening of Hp should be based on more accurate and more comprehensive testing than UBT or SAT alone. The GastroPanel® is such test, being completely devoid of the known serious shortcomings of UBT and SAT.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Helicobacter Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Grecia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Helicobacter Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Grecia